Zolbetuximab+mFOLFOX6 as First-Line (1L) treatment for patients (Pts) with Claudin-18.2+(CLDN18.2+) / HER2-Locally Advanced (LA) unresectable or metastatic Gastric or Gastroesophageal Junction (mG/GEJ) adenocarcinoma: primary results from Phase 3 SPOTLIGHT Study

F. Lordick, K. Shitara,Y. -J Bang, P. Enzinger, D. Ilson, M. A. Shah,E. Van Cutsem,R. -H Xu, G. Aprile, J. Xu, J. Chao, R. Pazo-Cid,Y. K. Kang, J. Yang, D. Moran, P. Bhattacharya, A. Arozullah, J. W. Park, J. Ajani

ONCOLOGY RESEARCH AND TREATMENT（2023）

引用 0|浏览0

暂无评分

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要